CorMedix Inc. (CRMD) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US21900C3088
CorMedix Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 311.71 m USD |
| Gross profit | 275.75 m USD |
| Operating income | 150.14 m USD |
| EBIT | 148.95 m USD |
| Net income | 163.06 m USD |
| Diluted EPS – continuing operations | 2.04 USD |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
More stocks
- Nanjing Inform Storage Equip (603066.SS)
- Oriental Kopi Holdings Berhad (0338.KL)
- Whitefield Industrials Ltd (WHF.AX)
- Suzhou Longjie Special Fiber Co Ltd (603332.SS)
- Ningbo Tianyi Medical Appliance Co. Ltd. (301097.SZ)
- Lets Holding Group Co Ltd (002398.SZ)
- Linc AB (LINC.ST)
- JAKKS PACIFIC INC (JAKK)
- APAC Opto Electronics (4908.TWO)
- YTL Hospitality REIT (5109.KL)
- LX Holdings Corp. Pfd. (38380K.KS)
- APAQ Technology Co Ltd (6449.TW)
Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.